表紙
市場調查報告書
商品編碼
607619

裘馨氏肌肉萎縮症的全球市場分析

Global Market Study on Duchenne Muscular Dystrophy: Europe to Lead the Global Market in Terms of Revenue during 2017 - 2026

出版日期: | 出版商: Persistence Market Research | 英文 170 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球裘馨氏肌肉萎縮症的市場相關分析,疾病概要和市場結構,主要的推動及阻礙市場要素,市場規模、佔有率、成長率的變化與預測 (過去5年、今後10年份),各產品種類、各流通管道、各治療法及各地區詳細趨勢,目前市場競爭狀態,主要企業簡介等調查。

第1章 全球經濟的未來展望

第2章 摘要整理

第3章 全球裘馨氏肌肉萎縮症市場概要

  • 簡介
  • 市場規模與其預測 (以金額為準,總計15年份)
    • 年度成長率
  • 市場動態
  • 供應鏈
  • 流行病學
  • 新的治療方法的出現
  • 開發平台分析
  • 杜顯型/貝克氏肌肉萎縮症的患病人數:男性的情況
  • 現在臨床實驗中的產品
  • 大環境分析
  • 產品生命週期
  • 主要打入市場企業的市場影響 (集中度地圖):各地區

第4章 全球裘馨氏肌肉萎縮症市場分析與預測

  • 市場規模與其預測:各產品種類 (總計15年份)
    • NSAID (非類固醇消炎劑)
      • 市場收益額比較:各地區
      • 市場佔有率比較:各地區
      • 年度成長率比較:各地區
    • 皮質類固醇
    • 其他的產品
  • 市場規模與其預測:各流通管道 (總計15年份)
    • 院內藥局
    • 零售藥局
    • 線上藥局
  • 市場規模與其預測:各治療法 (總計15年份)
    • 變異抑制
    • 外顯子跳躍機制
    • 其他

第5章 北美的裘馨氏肌肉萎縮症市場分析與預測

  • 市場展望
  • 母體市場未來展望
  • 目標市場的未來展望
  • 市場收益額比較:各國 (總計15年份)
    • 美國
    • 加拿大
  • 市場收益額比較:各產品種類
  • 市場收益額比較:各流通管道
  • 市場收益額比較:各治療法

第6章 南美的裘馨氏肌肉萎縮症市場分析與預測

  • 市場收益額比較:各國 (總計15年份)
    • 巴西
    • 墨西哥
    • 其他

第7章 歐洲的裘馨氏肌肉萎縮症市場分析與預測

  • 市場收益額比較:各國 (總計15年份)
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他

第8章 日本的裘馨氏肌肉萎縮症市場分析與預測

  • 市場收益額比較:各國 (總計15年份)

第9章 亞太地區 (日本以外)的裘馨氏肌肉萎縮症市場分析與預測

  • 市場收益額比較:各國 (總計15年份)
    • 中國
    • 印度
    • 印尼
    • 韓國
    • 澳洲
    • 其他

第10章 中東、非洲的裘馨氏肌肉萎縮症市場分析與預測

  • 市場收益額比較:各國 (總計15年份)
    • 波灣合作理事會 (GCC) 各國
    • 以色列
    • 土耳其
    • 其他

第11章 市場佔有率,競爭環境,企業簡介

  • 各企業市場佔有率
  • 競爭環境
  • 企業簡介
    • Sarepta Therapeutics, Inc
    • Santhera Pharmaceuticals
    • PTC Therapeutics
    • Summit Therapeutics plc
    • FibroGen, Inc
    • ITALFARMACO S.p.A.

第12章 分析方法

第13章 免責聲明

目錄

Global Duchenne Muscular Dystrophy Market- Overview

Duchenne Muscular Dystrophy (DMD) is one of the most common types of genetic disorder that results in muscle degeneration. Currently there is no curative treatment for DMD, however, various organizations are investing in the research and development, in order to find an effective treatment for DMD. Gene therapy as the treatment for DMD is in an early stage of development.

The U.S. Food and Drugs Administration (FDA) in 2015 published guidelines for developing a drug for duchenne muscular dystrophy. Hence, these guidelines are expected to contribute towards new drug development to treat duchenne muscular dystrophy. Most of the DMD disorders can be detected during pregnancy, technically advanced devices are being developed for muscle biopsy test and prenatal tests for diagnosis. Also, small drugs for downstream defects are in clinical trials. However, lack of standardization to measure efficacy across all the stages of DMD and the high cost of novel drugs are hampering the growth of the global duchenne muscular dystrophy market.

Global Duchenne Muscular Dystrophy Market- Research Methodology

The report on the global duchenne muscular dystrophy market gives important perceptions on the overall market. The report offers critical insights focusing on the financial and technical details of the market. The market research report aims to provide key trends, various driving factors, opportunities in the market and factors hampering the market growth. The worldwide duchenne muscular dystrophy market analysis report includes market overview, growth, demand and research on the performance of the market in major regions across the globe.

Both primary and secondary research was done by the expert analysts to provide a forecast on the market including revenue, CAGR, and year-on-year growth along with the information that will impact the market in the long run. The primary research was done by conducting interviews with market experts and details provided by them were crosschecked with valid sources. While, financial reports, annual reports of the key companies and investor presentation formed the part of the secondary research.

The report also comprises SWOT analysis, Porter's Five Force analysis. The report also provides regional overview along with market segmentation along with the details on the most attractive segments in the global duchenne muscular dystrophy market.

The report also provides competitive landscape including profiles of the key players operating in the global duchenne muscular dystrophy market. The report offers details on the key players including financial overview, company overview, product portfolio, key developments and long-term and short-term strategies by businesses.

The global duchenne muscular dystrophy market is segmented on the basis of product type, distribution channel, therapy, and region. On the basis of product type, the market is segmented into NSAIDs, Corticosteroids, and other products. By distribution channel, the market segmentation includes Hospital Pharmacies, Retail Pharmacies, and online pharmacies.

Based on the therapy, the market is segmented into Mutation Suppression, Exon Skipping Approach, and other therapies. The global duchenne muscular dystrophy market segmented on the basis of region includes Europe, Japan, Latin America, Asia Pacific Excluding Japan (APEJ), North America, and the Middle East and Africa (MEA).

Table of Contents

1. Global Economic Outlook

2. Global Duchenne Muscular Dystrophy Market - Executive Summary

3. Global Duchenne Muscular Dystrophy Market Overview

  • 3.1. Introduction
    • 3.1.1. Global Duchenne Muscular Dystrophy Market Taxonomy
    • 3.1.2. Global Duchenne Muscular Dystrophy Market Definition
  • 3.2. Global Duchenne Muscular Dystrophy Market Size (US$ Mn) and Forecast, 2012-2026
    • 3.2.1. Global Duchenne Muscular Dystrophy Market Y-o-Y Growth
  • 3.3. Global Duchenne Muscular Dystrophy Market Dynamics
  • 3.4. Supply Chain
  • 3.5. Epidemiology
  • 3.6. Arrival of New Treatments
  • 3.7. Pipeline Assessment
  • 3.8. Prevalence of males with Duchenne and Becker Muscular Dystrophies
  • 3.9. Undergoing Studies on Products
  • 3.10. PESTLE Analysis
  • 3.11. Product Lifecycle
  • 3.12. Key Participants Market Presence (Intensity Map) By Region

4. Global Duchenne Muscular Dystrophy Market Analysis and Forecast 2012-2026

  • 4.1. Global Duchenne Muscular Dystrophy Market Size and Forecast By Product Type, 2012-2026
    • 4.1.1. NSAIDs Market Size and Forecast, 2012-2026
      • 4.1.1.1. Revenue (US$ Mn) Comparison, By Region
      • 4.1.1.2. Market Share Comparison, By Region
      • 4.1.1.3. Y-o-Y growth Comparison, By Region
    • 4.1.2. Corticosteroids Market Size and Forecast, 2012-2026
      • 4.1.2.1. Revenue (US$ Mn) Comparison, By Region
      • 4.1.2.2. Market Share Comparison, By Region
      • 4.1.2.3. Y-o-Y growth Comparison, By Region
    • 4.1.3. Other Product Types Market Size and Forecast, 2012-2026
      • 4.1.3.1. Revenue (US$ Mn) Comparison, By Region
      • 4.1.3.2. Market Share Comparison, By Region
      • 4.1.3.3. Y-o-Y growth Comparison, By Region
  • 4.2. Global Duchenne Muscular Dystrophy Market Size and Forecast By Distribution Channel, 2012-2026
    • 4.2.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.1.1. Revenue (US$ Mn) Comparison, By Region
      • 4.2.1.2. Market Share Comparison, By Region
      • 4.2.1.3. Y-o-Y growth Comparison, By Region
    • 4.2.2. Retail Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.2.1. Revenue (US$ Mn) Comparison, By Region
      • 4.2.2.2. Market Share Comparison, By Region
      • 4.2.2.3. Y-o-Y growth Comparison, By Region
    • 4.2.3. Online Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.3.1. Revenue (US$ Mn) Comparison, By Region
      • 4.2.3.2. Market Share Comparison, By Region
      • 4.2.3.3. Y-o-Y growth Comparison, By Region
  • 4.3. Global Duchenne Muscular Dystrophy Market Size and Forecast By Therapy, 2012-2026
    • 4.3.1. Mutation suppression Market Size and Forecast, 2012-2026
      • 4.3.1.1. Revenue (US$ Mn) Comparison, By Region
      • 4.3.1.2. Market Share Comparison, By Region
      • 4.3.1.3. Y-o-Y growth Comparison, By Region
    • 4.3.2. Exon skipping approach Market Size and Forecast, 2012-2026
      • 4.3.2.1. Revenue (US$ Mn) Comparison, By Region
      • 4.3.2.2. Market Share Comparison, By Region
      • 4.3.2.3. Y-o-Y growth Comparison, By Region
    • 4.3.3. others Market Size and Forecast, 2012-2026
      • 4.3.3.1. Revenue (US$ Mn) Comparison, By Region
      • 4.3.3.2. Market Share Comparison, By Region
      • 4.3.3.3. Y-o-Y growth Comparison, By Region

5. North America Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 5.1. North America Outlook
  • 5.2. North America Parent Market Outlook
  • 5.3. North America Target Market Outlook
  • 5.4. Revenue (US$ Mn) Comparison, By Country
    • 5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
    • 5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
  • 5.5. Revenue (US$ Mn) Comparison, By Product Type
  • 5.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 5.7. Revenue (US$ Mn) Comparison, By Therapy

6. Latin America Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 6.1. Latin America Outlook
  • 6.2. Latin America Parent Market Outlook
  • 6.3. Latin America Target Market Outlook
  • 6.4. Revenue (US$ Mn) Comparison, By Country
    • 6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
    • 6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
    • 6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
  • 6.5. Revenue (US$ Mn) Comparison, By Product Type
  • 6.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 6.7. Revenue (US$ Mn) Comparison, By Therapy

7. Europe Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 7.1. Europe Outlook
  • 7.2. Europe Parent Market Outlook
  • 7.3. Europe Target Market Outlook
  • 7.4. Revenue (US$ Mn) Comparison, By Country
    • 7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
    • 7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
    • 7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
    • 7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
    • 7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
    • 7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
  • 7.5. Revenue (US$ Mn) Comparison, By Product Type
  • 7.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 7.7. Revenue (US$ Mn) Comparison, By Therapy

8. Japan Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 8.1. Japan Outlook
  • 8.2. Japan Parent Market Outlook
  • 8.3. Japan Target Market Outlook
  • 8.4. Revenue (US$ Mn) Comparison, By Country
    • 8.4.1. Japan Market Size and Forecast (US$ Mn), 2012-2026
  • 8.5. Revenue (US$ Mn) Comparison, By Product Type
  • 8.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 8.7. Revenue (US$ Mn) Comparison, By Therapy

9. APEJ Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 9.1. APEJ Outlook
  • 9.2. APEJ Parent Market Outlook
  • 9.3. APEJ Target Market Outlook
  • 9.4. Revenue (US$ Mn) Comparison, By Country
    • 9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
    • 9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
    • 9.4.3. Indonesia Market Size and Forecast (US$ Mn), 2012-2026
    • 9.4.4. South Korea Market Size and Forecast (US$ Mn), 2012-2026
    • 9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
    • 9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
  • 9.5. Revenue (US$ Mn) Comparison, By Product Type
  • 9.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 9.7. Revenue (US$ Mn) Comparison, By Therapy

10. MEA Duchenne Muscular Dystrophy Market Size and Forecast, 2012-2026

  • 10.1. MEA Outlook
  • 10.2. MEA Parent Market Outlook
  • 10.3. MEA Target Market Outlook
  • 10.4. Revenue (US$ Mn) Comparison, By Country
    • 10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
    • 10.4.2. Israel Market Size and Forecast (US$ Mn), 2012-2026
    • 10.4.3. Turkey Market Size and Forecast (US$ Mn), 2012-2026
    • 10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
  • 10.5. Revenue (US$ Mn) Comparison, By Product Type
  • 10.6. Revenue (US$ Mn) Comparison, By Distribution Channel
  • 10.7. Revenue (US$ Mn) Comparison, By Therapy

11. Global Duchenne Muscular Dystrophy Market Company Share, Competition Landscape and Company Profiles

  • 11.1. Company Share Analysis
  • 11.2. Competition Landscape
  • 11.3. Company Profiles
    • 11.3.1. Sarepta Therapeutics, Inc
    • 11.3.2. Santhera Pharmaceuticals
    • 11.3.3. PTC Therapeutics
    • 11.3.4. Summit Therapeutics plc
    • 11.3.5. FibroGen, Inc
    • 11.3.6. ITALFARMACO S.p.A.

12. Research Methodology

13. Disclaimer

List of Tables

  • TABLE 1: Global Duchenne Muscular Dystrophy Market Value (US$ Mn), 2012-2017
  • TABLE 2: Global Duchenne Muscular Dystrophy Market Value (US$ Mn), 2018-2026
  • TABLE 3: Global Duchenne Muscular Dystrophy Market Value (US$ Mn) and Y-o-Y, 2017-2026
  • TABLE 4: Global NSAIDs Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 5: Global NSAIDs Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 6: Global NSAIDs Segment Market Share, By Region 2012-2017
  • TABLE 7: Global NSAIDs Segment Market Share, By Region 2018-2026
  • TABLE 8: Global NSAIDs Segment Y-o-Y, By Region 2017-2026
  • TABLE 9: Global Corticosteroids Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 10: Global Corticosteroids Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 11: Global Corticosteroids Segment Market Share, By Region 2012-2017
  • TABLE 12: Global Corticosteroids Segment Market Share, By Region 2018-2026
  • TABLE 13: Global Corticosteroids Segment Y-o-Y, By Region 2017-2026
  • TABLE 14: Global Other Products Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 15: Global Other Products Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 16: Global Other Products Segment Market Share, By Region 2012-2017
  • TABLE 17: Global Other Products Segment Market Share, By Region 2018-2026
  • TABLE 18: Global Other Products Segment Y-o-Y, By Region 2017-2026
  • TABLE 19: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 20: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 21: Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
  • TABLE 22: Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
  • TABLE 23: Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
  • TABLE 24: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 25: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 26: Global Retail Pharmacies Segment Market Share, By Region 2012-2017
  • TABLE 27: Global Retail Pharmacies Segment Market Share, By Region 2018-2026
  • TABLE 28: Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
  • TABLE 29: Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 30: Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 31: Global Online Pharmacies Segment Market Share, By Region 2012-2017
  • TABLE 32: Global Online Pharmacies Segment Market Share, By Region 2018-2026
  • TABLE 33: Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
  • TABLE 34: Global Mutation Suppression Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 35: Global Mutation Suppression Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 36: Global Mutation Suppression Segment Market Share, By Region 2012-2017
  • TABLE 37: Global Mutation Suppression Segment Market Share, By Region 2018-2026
  • TABLE 38: Global Mutation Suppression Segment Y-o-Y, By Region 2017-2026
  • TABLE 39: Global Exon Skipping Approach Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 40: Global Exon Skipping Approach Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 41: Global Exon Skipping Approach Segment Market Share, By Region 2012-2017
  • TABLE 42: Global Exon Skipping Approach Segment Market Share, By Region 2018-2026
  • TABLE 43: Global Exon Skipping Approach Segment Y-o-Y, By Region 2017-2026
  • TABLE 44: Global Others Therapies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 45: Global Others Therapies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 46: Global Others Therapies Segment Market Share, By Region 2012-2017
  • TABLE 47: Global Others Therapies Segment Market Share, By Region 2018-2026
  • TABLE 48: Global Others Therapies Segment Y-o-Y, By Region 2017-2026
  • TABLE 49: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 50: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 51: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 52: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 53: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 54: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 55: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 56: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • TABLE 57: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 58: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 59: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 60: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 61: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 62: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 63: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 64: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • TABLE 65: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 66: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 67: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 68: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 69: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 70: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 71: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 72: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • TABLE 73: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 74: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 75: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 76: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 77: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 78: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 79: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 80: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • TABLE 81: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 82: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 83: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 84: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 85: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 86: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 87: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 88: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • TABLE 89: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • TABLE 90: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • TABLE 91: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • TABLE 92: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • TABLE 93: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • TABLE 94: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • TABLE 95: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • TABLE 96: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026

List of Figures

  • FIG. 1: Global Duchenne Muscular Dystrophy Market Value (US$ Mn), 2012-2017
  • FIG. 2: Global Duchenne Muscular Dystrophy Market Value (US$ Mn) Forecast, 2018-2026
  • FIG. 3: Global Duchenne Muscular Dystrophy Market Value (US$ Mn) and Y-o-Y, 2017-2026
  • FIG. 4: Global NSAIDs Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 5: Global NSAIDs Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 6: Global NSAIDs Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 7: Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 8: Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 9: Global Corticosteroids Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 10: Global Other Products Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 11: Global Other Products Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 12: Global Other Products Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 13: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 14: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 15: Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 16: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 17: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 18: Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 19: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 20: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 21: Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 22: Global Mutation Suppression Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 23: Global Mutation Suppression Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 24: Global Mutation Suppression Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 25: Global Exon Skipping Approach Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 26: Global Exon Skipping Approach Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 27: Global Exon Skipping Approach Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 28: Global Others Therapies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 29: Global Others Therapies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 30: Global Others Therapies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 31: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 32: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 33: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 34: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 35: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • FIG. 36: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 37: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 38: North America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • FIG. 39: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 40: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 41: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 42: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 43: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • FIG. 44: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 45: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 46: Latin America Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • FIG. 47: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 48: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 49: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 50: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 51: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • FIG. 52: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 53: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 54: Europe Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • FIG. 55: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 56: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 57: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 58: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 59: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 60: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 61: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 62: Japan Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • FIG. 63: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 64: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 65: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 66: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 67: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • FIG. 68: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 69: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 70: APEJ Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026
  • FIG. 71: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2012-2017
  • FIG. 72: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Country 2018-2026
  • FIG. 73: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2012-2017
  • FIG. 74: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Product Type 2018-2026
  • FIG. 75: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2012-2017
  • FIG. 76: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Distribution Channel2018-2026
  • FIG. 77: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2012-2017
  • FIG. 78: MEA Duchenne Muscular Dystrophy Market Value (US$ Mn), By Therapy 2018-2026